Eric Vivier

Eric Vivier is a French professor of immunology at Aix-Marseille and hospital practitioner^[1] at Marseille Public University Hospital. He is also Chief Scientific Officer at Innate Pharma,^[2] coordinator of the Marseille Immunopôle immunology cluster,^[3] and president of the Paris-Saclay Cancer Cluster.^[4][5] Vivier is a member of the expert panel of the European Research Council and serves on committees for several pharmaceutical and biotechnology companies.^[6][7][8][9]

Eric Vivier
Born	Clamart, France
Nationality	French
Scientific career
Fields	Immunology

Early life and education

Eric Vivier was born in Clamart, France.^[10] Vivier is a Doctor of Veterinary Medicine (DVM). He graduated from the Ecole Nationale Vétérinaire de Maisons-Alfort and received his doctoral degree in immunology from Paris XI University.^[11] He completed postdoctoral training as a Fogarty International Center Research Fellow at Harvard Medical School with Paul J. Anderson and Stuart F. Schlossman at the Dana-Farber Cancer Institute.^[12][13]

Career

Vivier joined Aix-Marseille University as a professor at the Centre d'Immunologie de Marseille-Luminy (CIML) in 1993, becoming its director in 2008^[14] until 2017.^[2] He co-founded the biotech company Innate-Pharma in 1999^[15] and in 2014, he co-founded the Marseille-Immunopole,^[16][17][18] an immunology cluster connecting basic research, therapeutic innovation, and industrial development in the Aix-Marseille region. Vivier was the chief scientific officer of Innate Pharma in January 2018 and in 2022, he served as president of the PSCC (Paris Saclay Cancer Cluster^[5][4]).

Vivier's research has focused on natural killer (NK) cells and innate lymphoid cells (ILCs).^[19][20][21] His work has contributed to the understanding of the development, function, and therapeutic potential of these cells. His early research investigated the mechanism of inhibitory MHC class I receptors on NK cells and the concept of ITIM-bearing molecules. His group identified the ITAM-bearing polypeptide, KARAP/DAP12/Tyrobp.^[22] This research led to the discovery and characterization of ILC3 cells in human and mouse intestines.

Awards and honors

• French National League Against Cancer Award (1996, 2004, and 2013)^[23]
• National Award and Tremplins Rhône-Poulenc Award for Biotech start-ups (1999)
• Lucien Tartois Award from the Fondation pour la Recherche Médicale (1999)^[24]
• Jacques Oudin Award from the French Society for Immunology (2003)^[25]
• Deutsche Gesellschaft für Immunologie/EFIS Award (2004)^[26]
• Grand Prix Turpin in Oncology (2008)^[27]
• Grand Prix Charles Oberling in Oncology (2010)^[28]
• Australasian Society for Immunology, Visiting Speaker Programme Award (2015)
• Thomson Reuters Highly Cited Researcher (2015, 2016, 2017)^[29]

Vivier became a senior fellow of the Institut Universitaire de France in 2007 and was elected to the French National Academy of Medicine in 2013.^{[citation needed]} In 2016, he was awarded honorary citizen of Cassis, Chevalier de la Légion d’Honneur^[30] and Ambassadeur de la ville de Marseille.^[31]